Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-07-25 DOI:10.2147/cmar.s466633

Zhenyu Li, Jimin Liu, Haishan Cui, Wenlong Qi, Yangyang Tong, Tan Wang

{"title":"Astragalus membranaceus: A Review of Its Antitumor Effects on Non-Small Cell Lung Cancer","authors":"Zhenyu Li, Jimin Liu, Haishan Cui, Wenlong Qi, Yangyang Tong, Tan Wang","doi":"10.2147/cmar.s466633","DOIUrl":null,"url":null,"abstract":"Abstract: The rising global morbidity and mortality rates of non-small cell lung cancer (NSCLC) underscore the urgent need for more effective treatments. Current therapeutic modalities—including surgery, radiotherapy, chemotherapy, and targeted therapy—face several limitations. Recently, Astragalus membranaceus, a traditional Chinese medicine (TCM), has captured significant attention due to its broad pharmacological properties, such as immune regulation, anti-inflammatory effects, and the modulation of reactive oxygen species (ROS) and enzyme activities. This review delivers a comprehensive summary of the most recent advancements and ongoing applications of Astragalus membranaceus in NSCLC treatment, underlining its potential for integration into existing treatment protocols. It also highlights essential areas for future research, including the elucidation of its molecular mechanisms, optimization of dosage and administration, and evaluation of its efficacy and safety alongside standard therapies, all of which could potentially improve therapeutic outcomes for NSCLC patients. Keywords: non-small cell lung cancer, Astragalus membranaceus, antitumor activity, immunoregulation, cisplatin ","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"113 1","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/cmar.s466633","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract: The rising global morbidity and mortality rates of non-small cell lung cancer (NSCLC) underscore the urgent need for more effective treatments. Current therapeutic modalities—including surgery, radiotherapy, chemotherapy, and targeted therapy—face several limitations. Recently, Astragalus membranaceus, a traditional Chinese medicine (TCM), has captured significant attention due to its broad pharmacological properties, such as immune regulation, anti-inflammatory effects, and the modulation of reactive oxygen species (ROS) and enzyme activities. This review delivers a comprehensive summary of the most recent advancements and ongoing applications of Astragalus membranaceus in NSCLC treatment, underlining its potential for integration into existing treatment protocols. It also highlights essential areas for future research, including the elucidation of its molecular mechanisms, optimization of dosage and administration, and evaluation of its efficacy and safety alongside standard therapies, all of which could potentially improve therapeutic outcomes for NSCLC patients.

Keywords: non-small cell lung cancer, Astragalus membranaceus, antitumor activity, immunoregulation, cisplatin

查看原文本刊更多论文

黄芪：黄芪对非小细胞肺癌的抗肿瘤作用综述

摘要：非小细胞肺癌（NSCLC）在全球的发病率和死亡率不断上升，突出表明迫切需要更有效的治疗方法。目前的治疗方法--包括手术、放疗、化疗和靶向治疗--面临着一些局限性。最近，传统中药黄芪因其广泛的药理特性，如免疫调节、抗炎作用、调节活性氧（ROS）和酶活性等，引起了广泛关注。本综述全面总结了膜荚黄芪在治疗 NSCLC 方面的最新进展和持续应用，强调了其融入现有治疗方案的潜力。它还强调了未来研究的重要领域，包括阐明其分子机制、优化剂量和给药以及评估其与标准疗法并用的疗效和安全性，所有这些都有可能改善 NSCLC 患者的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464